Arch Biopartners Inc.ARCH.V
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada · archbiopartners.com
Arch Biopartners Inc. is a Toronto-based clinical-stage biopharmaceutical company developing novel therapeutics for acute and chronic kidney disease. Its lead candidate LSALT Peptide is in Phase 2 clinical trials for inflammation-related acute kidney injury in cardiac surgery patients, and it also develops cilastatin for toxin-related acute kidney injury via dipeptidase-1 inhibition.
Key ratios
FCF / Sales
-968.4%TTM
2025
-574.2%2024
-109.9%2023
-11.8%
Net margin
-183.0%TTM
2024
-184.8%2023
-167.7%
ROA
-524.0%TTM
2025
-136.3%2024
-205.0%2023
-201.9%
Recent news
Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans
Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
Arch Biopartners Closes Non-Brokered Private Placement
Arch Biopartners Arranges Non-Brokered Private Placement
Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial
Track ARCH.V in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer